

Advances in Uterine Leiomyoma Research: 2nd NIH International Congress



Office of Research on Women's Health
National Institutes of Health

U.S. Department of Health and Human Services

February 24-25, 2005
National Institutes of Health
William H. Natcher Conference Center, Building 45
Bethesda, MD

Advances in Uterine Leiomyoma Research
2nd NIH International Congress:
National Institute of Environmental Health Sciences
Attn: Dr. Darlene Dixon
MD C2-09
P.O. Box 12233
RTP, NC 27709

Organizing Committee

Congress Co-Chairs

Dr. Kenneth Olden NIEHS, NIH
Dr. Vivian W. Pinn ORWH, NIH

Program Co-Chairs

Dr. J. Carl Barrett NCI, NIH
Dr. Barbara J. Davis (Formerly NIEHS) AstraZeneca
Dr. Darlene Dixon NIEHS, NIH
Dr. Estella Parrott NICHD, NIH
Dr. James Segars NICHD, NIH

Abstracts Chairs

Dr. Susan Meikle, Chair AHRQ
Dr. Shelia McClure, Co-Chair NCR, NIH

Steering Committee

Ms. Duiona R. Baker	Ms. Lisa Kaeser
Dr. Lisa Begg	Ms. Mary Lawrence
Dr. Rosaly Correa-de-Araujo	Dr. Phyllis Leppert
Dr. Loretta Finnegan	Ms. Sabrina Matoff
Ms. Mary Gant	Dr. Lynnette Nieman
Ms. Yvonne Green	Mr. Colin Pollard
Dr. Joan Harmon	Dr. Ahalya Premkumar
Dr. Wanda K. Jones	Ms. Joyce Rudick
Dr. Joseph Kaczmarczyk	Dr. Maura Whiteman
	Dr. Susan Wood

Sponsors

National Institutes of Health

Office of Research on Women's Health
National Institute of Environmental Health Sciences
National Institute of Child Health and Human Development
National Cancer Institute
National Institute of Biomedical Imaging and Bioengineering
National Center for Research Resources
Agency for Healthcare Research and Quality
Centers for Disease Control and Prevention
Food and Drug Administration
Health Resources and Services Administration
Office on Women's Health, Office of the Secretary
Substance Abuse and Mental Health Services Administration

Conference Objectives

Uterine leiomyoma (fibroids) are the most common gynecologic neoplasm in women of reproductive age. As the number one cause of hysterectomy, they have a profound negative impact on women's health. Uterine leiomyoma are hormonally dependent and as such are a potential target for endocrine active compounds in the environment.

The goal of this conference is to bring together researchers working in the fields of biomedicine, epidemiology, basic research, therapeutics, and translational medicine to foster an exchange of scientific information among members of the uterine leiomyoma research and health care communities. Participants will be drawn from academia, medical centers, government and industry.

Topics to be covered include Clinical Experience and Therapeutic Strategies, Epidemiology, Clinical Trials, Pathogenesis of Smooth Muscle Tumors, and Molecular and Genetic Characteristics.

FINAL PRELIMINARY AGENDA

- 8:00-8:15 Welcome and Introductory Comments
-
- Session I: Disease Burden and Manifestations**
Chair: Phyllis Leppert, M.D., NICHD
- 8:15-9:00 Opening Keynote: Clinical Manifestations and Outcomes of Uterine Leiomyoma
Lee A. Learman, M.D., Ph.D, University of California, San Francisco
- 9:00-9:30 Molecular Characterization of Uterine Leiomyoma
J. Carl Barrett, Ph.D., National Cancer Institute
- 9:30-10:00 Panel and General Discussion With the Patients' Perspective
- 10:00-10:30 *Break and Poster Set-up*
-
- Session II: Epidemiology and Genetics**
Chair: Ivo Brosens, M.D., Ph.D., Leuven Institute for Fertility and Embryology
- 10:30-11:00 The NIEHS Uterine Fibroid Study
Donna Day Baird, Ph.D., NIEHS
- 11:00-11:30 Genetic Links
Cynthia Morton, Ph.D., Brigham and Women's Hospital
- 11:30-12:00 Hereditary Fibroids
Marston Linehan, M.D., National Cancer Institute
- 12:00-12:30 Panel and General Discussion
- 12:30-1:30 *Lunch (on your own)*
-
- Session III. Pathobiology of Fibroids**
Chair: Darlene Dixon, DVM, Ph.D., NIEHS
- 1:30-2:00 The Fibroid Growth Study
Barbara J. Davis, V.M.D, Ph.D., AstraZeneca
- 2:00-2:30 New Insights into Signaling Pathways that Regulate Leiomyoma Growth
Romana Nowak, Ph.D., University of Illinois
- 2:30-3:00 Developmental Programming: How Early Life Exposure Influences the Occurrence of Leiomyoma in Adults
Cheryl Walker, Ph.D., M.D. Anderson Cancer Center
- 3:00-3:30 Panel and General Discussion
-
- 3:30-5:00 **Session IV: Poster Presentations**
Chair: Shelia McClure, Ph.D., NCRR
Poster Coordinator: Karen Haneke, Integrated Laboratory Systems, Inc.

- 8:00-8:15 Introductory Comments
-
- Session V: Advances in Clinical Management and Translational Frontiers**
Chair: Estella Parrott, M.D., M.P.H., NICHD
- 8:15-8:45 What Do We Really Know About Management of Fibroids?
Katherine E. Hartmann, M.D., Ph.D., University of North Carolina at Chapel Hill
- 8:45-9:15 Alternatives to Hysterectomy
Valerie Montgomery Rice, M.D. Meharry Medical College
- 9:15-10:15 Translational Frontiers: Innovation in Fibroid Treatments for the 21st Century
Elizabeth A. Stewart, M.D., Brigham and Women's Hospital
- 10:15-10:45 Panel and General Discussion
- 10:15-10:30 *Break*
-
- Session VI. Clinical Trials and Tribulations**
Chair: Colin Pollard, FDA
- 10:30-10:40 Opening Remarks
- 10:40-10:55 Use of Antiprogestins for Treatment of Uterine Fibroids, Clinical Trials
Kevin Fiscella, M.D., University of Rochester
- 10:55-11:10 Effectiveness of Asoprisnil in Treating Fibroids
Kristof Chwalisz, M.D., Ph.D., TAP Pharmaceutical Products, Inc.
- 11:10-11:20 A Uterine Fibroid Symptom QoL Scoring Instrument
James Spies, M.D., Georgetown University
- 11:20-11:35 Clinical Trial Design & Small Studies: a Coordinating Center Perspective
Kay Dickersin, Ph.D., Brown University
- 11:35-11:50 Uterine Fibroids – Clinical Trial Design & Small Studies: A Clinical Perspective
Keith B. Isaacson, M.D., Newton Wellesley Hospital
- 11:50-12:30 Panel Discussion
- 12:30-1:30 *Lunch (on your own)*
-
- Session VII. New Therapeutic Targets**
Chair: Cheryl Walker, Ph.D., University of Texas M.D. Anderson Cancer Center
- 1:30-2:00 TGF β Collagen-Keloid and Abnormal Mature Collagen Hypothesis
James Segars, M.D., NICHD
- 2:00-2:30 Regulation of Estrogen Biosynthesis in Uterine Fibroids
Serdar Bulun, M.D., Northwestern University
- 2:30-3:00 Panel and General Discussion
- 3:00-3:15 *Break*

- Session VIII. Hot Topics and Research**
Chair: Susan Meikle, M.D., M.S.P.H., AHRQ
- 3:15-3:30 Volume Estimation and Tracking Over Time (VETOT): Framework and Application to the Fibroid
Jean-Philippe Guyon, M.S.C.S., Integrated Laboratory Systems, Inc.
- 3:30-3:45 The Fibroid Registry for Outcomes Data (FIBROID) for Uterine Artery Embolization: Mid-term Clinical Outcomes
James Spies, M.D., Georgetown University
- 3:45-4:00 A Functional Polymorphism in Catechol-O-Methyl Transferase Gene Explains Increased Risk of Uterine Leiomyomas in Black Americans
Ayman Al-Hendy, M.D., Ph.D., University of Texas Medical Branch at Galveston
- 4:00-4:15 Large Uterine Leiomyomata: Spatial Distribution of the Tumorigenic Factors
Jian-Jun Wei, M.D., New York University
-
- Session IX. Charting the Course**
Chair: Barbara Davis, V.M.D., Ph.D., AstraZeneca
- 4:15-5:15 Panel Discussion
Estella Parrott, M.D., M.P.H., NICHD
Phyllis Leppert, M.D., NICHD
J. Carl Barrett, Ph.D., National Cancer Institute
Susan Meikle, M.D., M.S.P.H., AHRQ
Ms. Carla Dionne, National Uterine Fibroids Foundation and Audience Discussants
- 5:15-5:30 Closing Remarks

Contact Information

Integrated Laboratory Systems, Inc.
Attn: Heather Vahdat
P.O. Box 13501
Research Triangle Park, NC 27709
Email: hvahdat@ils-inc.com
Phone: 919.281.1110 x706
Fax: 919.281.1118

Register on-line at:
<http://www4.od.nih.gov/orwh/uterinefibroidmtg.html>